Circadian Technologies Limited (ASX: CIR) is an Australian biotechnology company developing innovative, biologics-based therapies for the treatment of cancer and other serious human illnesses.
 
Circadian owns an extensive portfolio of products and intellectual property related to Vascular Endothelial Growth Factors (VEGFs), a class of proteins that play a critical role in regulating tumour blood supply. These programs are conducted through Vegenics Ltd, a wholly-owned subsidiary of Circadian.

Videos

Dec,2011 09:30 AM
Circadian’s continuing clinica..
19 Dec 2011 – Circadian Technologies Limited (ASX:CIR), CEO and managing director, Robert Klupacs, talks about applications for its VGX-100 therapy in the treatment of a range of solid tumours, its phase 1 and 2 clinical program and partnerships for commercialisation.
Dec, 19 2011 - 19 Dec 2011 – Circadian Technologies Limited (ASX:CIR), CEO and managing director, Robert Klupacs, talks about applications for its VGX...
Feb, 11 2011 - 11 Feb 2011 – Circadian Technologies Limited (ASX:CIR), CEO, Robert Klupacs, explains what the deal means, reports on its successful pa...

Circadian (ASX:CIR)

Company Directors

Mr Carlo Montagner (Non Exec. Director)
Mr Dominique Fisher (Chairman, Non Exec. Director)
Mr Don Clarke (Non Exec. Director)
DR. Errol Malta (Non Exec. Director)
Mr Robert Klupacs (Managing Director, CEO)
Ms Tina McMeckan (Non Exec. Director)

Contact Information

Phone: +61 3 9826 0399
Email: info@circadian.com.au
Website: http://www.circadian.com.au
Address
Level 1, 10 Wallace Avenue Toorak, Victoria, Australia, 3142

Media Releases

Latest Company News